Economic Evaluation of Smoking Cessation Strategies within Lung Cancer Screening Programs
Background
Lung cancer remains a leading cause of cancer mortality in the US, with over 80% of cases linked to smoking. The integration of smoking cessation interventions into lung cancer screening programs is crucial for enhancing patient outcomes. Recent guidelines from the US Preventive Services Task Force emphasize the importance of concurrent cessation support for individuals eligible for lung cancer screening.
Data Highlights
The analysis of four randomized clinical trials revealed that smoking cessation interventions significantly increased quit rates among participants. The trials included diverse populations and assessed a range of cessation strategies, including behavioral counseling and pharmacotherapy. Key metrics evaluated included the number of participants who achieved cessation at various follow-up intervals and the cost-effectiveness of the interventions over time.
Key Findings
Four randomized clinical trials were analyzed, comprising 23 intervention arms focused on smoking cessation.
Interventions included counseling and pharmacotherapy, with varying intensities of support.
Short-term cost per quit and long-term cost-effectiveness were assessed for different cessation strategies.
The analysis linked empirical trial data with microsimulation models to project health and economic outcomes.
High-quality evidence on short-term cessation outcomes was obtained, although long-term consequences were not assessed in every trial.
Clinical Implications
Healthcare providers should consider integrating evidence-based smoking cessation strategies into lung cancer screening protocols.
Conclusion
The economic evaluation of smoking cessation strategies within lung cancer screening programs highlights the need for further research on the effectiveness of tailored interventions.
Related Resources & Content
Fu et al, JAMA Pulmonary Medicine, 2023 -- Optimizing Tobacco Cessation Treatment With Lung Cancer Screenings
The ASCO Post, 2022 -- Study Finds High-Intensity Intervention Helped One-Third of Participants in Lung Cancer Screening Program to Quit Smoking
The ASCO Post, 2023 -- Lung Cancer Screening May Be More Cost-Effective When Using Risk Model–Based Strategies
US Preventive Services Taskforce -- Recommendation: Lung Cancer: Screening
The ASCO Post — Lung Cancer Screening and Possible Unappreciated Benefits
Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening
Smoking Cessation Interventions in the Lung Cancer Screening Setting: A Randomized Clinical Trial
Recommendation: Lung Cancer: Screening | United States Preventive Services Taskforce
by Pianpian Cao, Laney Smith, Emma Tian, Lou-Anne Chichester, Elizabeth Schofield, Randi M. Williams, Rafael Meza, Benjamin A. Toll, Jamie Ostroff, Elena B. Elkin, Steven S. Fu, Stephanie R. Land, Kathryn L. Taylor, Jinani Jayasekera
Baptist Health Herbert Wertheim Cancer Institute has launched Eon, an AI-enabled software platform that analyzes radiology reports and helps identify and prioritize incidental findings for clinical review, in an effort to support timely, coordinated patient care.